Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Conditions:   Metastatic Non Small Cell Lung Cancer;   Advanced Non Small Cell Lung Cancer
Interventions:   Drug: MRTX849;   Drug: Docetaxel
Sponsor:   Mirati Therapeutics Inc.
Recruiting